- Indobufen
-
- $0.00 / 1Kg/Bag
-
2026-02-03
- CAS:63610-08-2
- Min. Order: 1KG
- Purity: 99%minHPLC
- Supply Ability: 1000KG
- Indobufen
-
- $64.00 / 500mg
-
2026-02-01
- CAS:63610-08-2
- Min. Order:
- Purity: 99.63%
- Supply Ability: 10g
- Indobufen
-
- $0.00 / 1kg
-
2026-01-27
- CAS:63610-08-2
- Min. Order: 1kg
- Purity: 99% up by HPLC
- Supply Ability: 20tons
|
| | Indobufen Basic information |
| | Indobufen Chemical Properties |
| Melting point | 182-184° | | Boiling point | 518.1±50.0 °C(Predicted) | | density | 1.275±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,Room Temperature | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 4.39±0.10(Predicted) | | color | White | | InChI | InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22) | | InChIKey | AYDXAULLCROVIT-UHFFFAOYSA-N | | SMILES | O=C1C2C=CC=CC=2CN1C1C=CC(C(CC)C(=O)O)=CC=1 | | CAS DataBase Reference | 63610-08-2(CAS DataBase Reference) | | EPA Substance Registry System | Benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-.alpha.-ethyl- (63610-08-2) |
| | Indobufen Usage And Synthesis |
| Description | Indobufen is a platelet aggregation inhibitor related to the antiinflammatory agent
indoprofen. It has shown clinical efficacy in peripheral artery disease, in
prevention of deep vein thrombosis after myocardial infarction, and in blocking
excercise-induced increase in platelet aggregation in angina patients. | | Chemical Properties | Crystallized from methanol, melting point 182-184°C. | | Originator | Erbamont (Italy) | | Uses | Indobufen is a platelet aggregation inhibitor. Indobufen is the anticoagulant drug and platelet aggregation inhibitor, which has anti-inflammatory analgesic effect. Indobufen is used as an antithrombotic. | | Definition | ChEBI: Indobufen is a member of isoindoles. | | Brand name | IBUSTRIN | | Clinical Use | A reversible but very potent inhibitor of platelet COX-1 activity,
was shown to have comparable clinical efficacy to that of aspirin in prevention of DVT after
myocardial infarction and in blocking exercise-induced increase in platelet aggregation. In the
secondary prevention of thromboembolic events, 100 or 200 mg of indobufen twice daily is as
effective as warfarin or aspirin in patients with or without atrial fibrillation. Currently,
indobufen is only available for routine clinical use in Europe. |
| | Indobufen Preparation Products And Raw materials |
|